From E. Randolph Broun, MD, a noted medical oncologist, hematologist and blood and marrow transplant specialist

December 3, 2020

Two years ago, the cancer experts at OHC were the first independent adult cancer group in the region to introduce the revolutionary treatment, CAR T-cell therapy, for adults. Since that noteworthy day, our researchers have made some great strides in expanding and improving this potentially lifesaving treatment.

Initially, CAR-T had side effects that required it to be administered in an inpatient setting. We would monitor patients and immediately administer treatment if patients experienced the side effects. Since then, there have been great advancements in this ground-breaking treatment. Now, we’re evaluating new forms of CAR-T. They’re milder and have fewer side effects so, as a result, it is now an option for more patients and we’re able to administer it in an outpatient setting. We’re evaluating these new forms of CAR-T through our nationally recognized clinical trials program.

We’re also looking at more applications for CAR-T. There is increasing excitement in the development of what is known as “off the shelf” CAR-T products. Currently, it takes 3 – 4 weeks to develop CAR-T using the patient’s own T-cells. If we can use a healthy donor’s T-cells, the treatment would be available within 72 hours.

CAR-T also has the potential to treat solid tumors such as breast, colon, lung and prostate cancers.

At OHC, our blood cancer experts have long been leaders in bringing cancer treatments to the region for adults with blood cancers. OHC was instrumental in bringing a world class blood and marrow transplant program to the region. We created a nationally recognized clinical trials program to offer patients access to the newest, most promising treatments like CAR-T. We continue to lead in the development and availability of new treatments such as immunotherapies and cellular therapies. To learn more about OHC, or to request a second opinion, visit ohcare.com or call 1-888-649-4800.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *